SS
KPTI icon

SBI Securities’s Karyopharm Therapeutics KPTI Stock Holding History

SBI Securities’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$373 Sell
67
-7
-9% -$53 ﹤0.01% 2998
2025
Q4 		$545 Hold
74
– – ﹤0.01% 2844
2025
Q3 		$484 Hold
74
– – ﹤0.01% 2982
2025
Q2 		$319 Hold
74
– – ﹤0.01% 3151
2025
Q1 		$277 Buy
74
+26
+54% +$222 ﹤0.01% 3103
2024
Q4 		$485 Buy
+48
New +$580 ﹤0.01% 2900

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SBI Securities's KPTI Position: Q1 2026 in Review

SBI Securities reduced its Karyopharm Therapeutics (KPTI) stake by 9.5% in Q1 2026, selling an estimated $53 and leaving 67 shares worth $373. The position accounts for ﹤0.01% of the portfolio, ranked #2998.

SBI Securities first reported a position in KPTI in Q4 2024 and has held it in 6 quarters since. The position peaked at $545 in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • SBI Securities held 67 shares of Karyopharm Therapeutics worth $373 as of Q1 2026.
  • SBI Securities sold 7 Karyopharm Therapeutics shares in Q1 2026, an estimated $53.
  • Karyopharm Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #2998 holding.
  • SBI Securities first reported a position in Karyopharm Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Karyopharm Therapeutics position peaked at $545 in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.